APR 29, 2016 11:39 AM PDT

3D NuRD Complex Related to Cancer Progression

WRITTEN BY: Kara Marker
When the equilibrium of gene regulation is disrupted, whether by random mutation, ultraviolet light exposure, or another cause, the risk of abnormal cell division and tumor growth drastically increases. A new study from the University of Leicester describes a way to restore equilibrium and reduce incidence of genetic diseases.
 
MTA1, RBBP4, and HDAC1 are core protein components of a complex called NuRD, which is responsible for regulating the amount of protein made from transcription and translation processes. When these core proteins’ interactions are inhibited or communication is misconstrued, the complex falls out of equilibrium and diseases can sprout and progress.
 
The NuRD Complex

NuRD regulates gene expression through the control and maintenance of chromatin, the genetic material that forms chromosomes inside eukaryotic cell nuclei (Nature). Chromatin allows for DNA to be organized into tightly-wound complexes called histones, which then form nucleosomes. This highly-ordered structure is dependent on consistency and accuracy, so when one brick is out of place, the whole system struggles to function properly.
 
In hopes to both understand the three-dimensional structure of the NuRD complex proteins as well as characterize their molecular nature, University of Leicester researchers studied images using electron microscopy. Their results were recently published in the journal eLIFE.
 
HDAC1 and MTA1 are known to exist at high levels in some incidences of cancer, and studying the interaction between these proteins as well as the relationship between MTA1 and RBBP4 in cancer patients and healthy patients could give the researchers a clue on how to protect disease-preventing equilibrium.
 
Electron microscopy showed an “extensive interface” between MTA1 and RBBP4. The three-dimensional images also showed a “repression complex” in cases where equilibrium was disrupted from NuRD complex-related activity. Specifically, the findings showed a second recruitment site within MTA1 for RBBP4, not known to exist before this study. Based on the different combinations of conformations between the three core proteins, the complexes are able to bind to different histones at different times. Understanding the components of this repression complex and the entire “architecture” of the NuRD complex will help scientists identify which mechanisms they should be targeting as a treatment option.
 
“An understanding [of] the exact mechanism by which the NuRD complex assembles and functions could make it an attractive target for developing novel and specific anti-cancer therapeutics and treatment for a range of genetic diseases,” said University of Leicester’s Dr. Christopher Millard.
 
Now that the University of Leicester research team has developed a more complete model of the NuRD complex, they can move on to understanding what goes wrong in NuRD signaling in cases of cancer or genetic diseases.
 
 
Sources: University of Leister, eLIFE
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 23, 2019
Cancer
NOV 23, 2019
Can lithium heal damage from radiation?
Research suggests that lithium could play a role in minimizing the negative effects of radiation on the brain. The research was published in Molecular Psyc...
DEC 10, 2019
Cancer
DEC 10, 2019
Using anthrax to fight cancer?
Surprising research published recently in the International Journal of Cancer says anthrax may act as a potential bladder cancer treatment. Yes, you read c...
JAN 02, 2020
Drug Discovery & Development
JAN 02, 2020
FDA Approves Ovarian Cancer Drug to Treat Pancreatic Cancer
In 2019, an estimated 46,000 Americans died from pancreatic cancer. Now, the Food and Drug Administration (FDA) has approved Lynparza, an ovarian cancer dr...
JAN 09, 2020
Drug Discovery & Development
JAN 09, 2020
Can Cancer Drugs Treat Lung Damage?
Can therapeutics used in the treatment of cancer be a breakthrough for pulmonary disease? Specifically, chronic obstructive pulmonary disease (COPD)? &ldqu...
FEB 08, 2020
Cancer
FEB 08, 2020
Magic mushrooms help cancer patients' depression
A follow-up to a study originally published in the Journal of Psychopharmacology in 2016 reports the long-term benefits of a one-time, single-dose tre...
FEB 13, 2020
Cancer
FEB 13, 2020
Can Ebola help treat glioblastomas?
You might want to sit down for this. New research published in the Journal of Virology has named a surprising new ally to brain tumors: Ebola. Yes, yo...
Loading Comments...